# A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

> **NCT05624554** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 300 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Nemtabrutinib
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Bendamustine
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Truxima
- **BIOLOGICAL:** Ruxience
- **BIOLOGICAL:** Riabni

## Key facts

- **NCT ID:** NCT05624554
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-16
- **Primary completion:** 2027-05-19
- **Final completion:** 2031-03-17
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624554, "A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05624554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*